Jerini Announces Research Collaboration Between Jerini Ophthalmic and UCL Institute of Ophthalmology Investigating New Treatments for AMD
December 07, 2007 05:37 ET | Jerini AG
BERLIN, Dec. 7, 2007 (PRIME NEWSWIRE) -- Jerini AG (Frankfurt:JI4) announced today that Jerini Ophthalmic, Inc., its wholly-owned U.S. subsidiary, signed a research collaboration agreement with...
Jerini Reports Financial Results for First Nine Months of 2007
November 14, 2007 03:18 ET | Jerini AG
BERLIN, Nov. 14, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) reported financial results according to International Financial Reporting Standards (IFRS) for the first nine months ended September 30,...
Jerini Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review
October 29, 2007 06:35 ET | Jerini AG
BERLIN, Oct. 29, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today the submission of its electronic New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE)...
Jerini Ophthalmic Treats First Patient in Phase I Trial for Age-related Macular Degeneration
October 09, 2007 03:11 ET | Jerini AG
BERLIN, Oct. 9, 2007 (PRIME NEWSWIRE) -- Jerini AG (Frankfurt:JI4) announced today that its wholly-owned subsidiary, Jerini Ophthalmic, Inc., has treated the first patient in its Phase I clinical...
Jerini Initiates FDA Submission Process of New Drug Application For Icatibant in the Treatment of HAE
October 08, 2007 04:45 ET | Jerini AG
BERLIN, Oct. 8, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the complete New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE) has been sent to...
Jerini Regains Commercialization Rights to Icatibant for the Treatment of Hereditary Angioedema in North America
September 04, 2007 07:40 ET | Jerini AG
BERLIN, Sept. 4, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today the termination of the license agreement between its affiliate, Jerini US, Inc., and Kos Life Sciences, Inc. for the...
Jerini Receives EMEA Filing Acceptance of Its Marketing Application for Icatibant in the Treatment of Hereditary Angioedema
August 16, 2007 09:23 ET | Jerini AG
BERLIN, Aug. 16, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today the acceptance of its Marketing Authorization Application (MAA) by the European Medicines Evaluation Agency (EMEA) on...
Jerini AG Reports First Half Financial Results for 2007
August 14, 2007 03:13 ET | Jerini AG
-- Submission of European Marketing Authorization Application completed -- Accelerated Assessment granted by EMEA for expedited review -- Completion of U.S. filing with FDA expected in third...
FDA Accepts Jerini Ophthalmic's IND of JSM 6427 For the Treatment of AMD
July 13, 2007 03:51 ET | Jerini AG
BERLIN, July 13, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the U.S. Food and Drug Administration (FDA) accepted the Investigative New Drug (IND) application submitted by...
Jerini AG Reports First Quarter Financial Results
May 15, 2007 03:22 ET | Jerini AG
BERLIN, May 15, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) reported financial results for the first quarter ended March 31, 2007. Under International Financial Reporting Standards (IFRS), revenues...